Meeting
2020 ASCO Virtual Scientific Program
A phase I study of AK112, a bispecific antibody that targets PD-1 and VEGF co-expressing T cells, in patients with advanced solid tumors.
Authors
Jermaine Coward
Icon Cancer Care, Brisbane, Australia
Jermaine Coward , Charlotte Rose Lemech , Anna Rachelle Austria Mislang , Sagun Parakh , Craig Underhill , Adnan Nagrial , Xiaoping Jin , Baiyong Li , Zhongmin Maxwell Wang , Kon Yew Kwek , Yu Xia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT04047290
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS3155)
DOI
10.1200/JCO.2020.38.15_suppl.TPS3155
Abstract #
TPS3155
Poster Bd #
219
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma.
First Author: Jiajian Liu
Poster
2022 ASCO Annual Meeting
Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody–drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress).
First Author: Amita Patnaik
Poster
2017 ASCO Annual Meeting
A phase I study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with advanced solid tumors.
First Author: Zhihong Chi
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Combining PD-1 blockade with T-cell redirecting bispecific antibodies for solid cancer therapy.
First Author: Chien-Hsing Chang